Analysis of breast cancer patients (n = 1084) showed that the OS, progression-free survival rate (PFI), and disease-specific survival rate (DSS) were lower in breast cancer patients expressing higher GOLT1B (Figure 2A). This evidence concerns the gene GOLT1B and breast cancer.